UPDATE 2-Hedge fund manager Kyle Bass loses challenges to pharma patents
0
NEW YORK, Aug 24 (Reuters) - Prominent hedge fund manager Kyle Bass's campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc's flagship multiple sclerosis drug, Ampyra.